Resultados de procura - Richard Pazdur

Limitar resultados
  1. 1
    Endpoints for Assessing Drug Activity in Clinical Trials

    Endpoints for Assessing Drug Activity in Clinical Trials por Richard Pazdur

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015

    Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015 por Susan Jin, Richard Pazdur, Rajeshwari Sridhara

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

    Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer por Martin H. Cohen, Robert Justice, Richard Pazdur

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

    FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia por Suzanne Demko, Jeffrey Summers, Patricia Keegan, Richard Pazdur

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Rare Cancer Trial Design: Lessons from FDA Approvals

    Rare Cancer Trial Design: Lessons from FDA Approvals por Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval

    U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval por Martin H. Cohen, John R. Johnson, Richard Pazdur

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease

    FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease por Min Lu, Martin H. Cohen, Dwaine Rieves, Richard Pazdur

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

    United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy por Robert C. Kane, Ann T. Farrell, Rajeshwari Sridhara, Richard Pazdur

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma

    FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma por Jeff Summers, Martin H. Cohen, Patricia Keegan, Richard Pazdur

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

    Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy por Robert C. Kane, Peter Bross, Ann T. Farrell, Richard Pazdur

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  11. 11
    FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer

    FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer por Martin H. Cohen, Joe Gootenberg, Patricia Keegan, Richard Pazdur

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

    Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) por Martin H. Cohen, Patricia Cortazar, Robert Justice, Richard Pazdur

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors

    Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors por Martin H. Cohen, Ann T. Farrell, Robert Justice, Richard Pazdur

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

    FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors por Leigh Marcus, Steven J. Lemery, Patricia Keegan, Richard Pazdur

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    FDA Drug Approval Summary: Nelarabine (Arranon®) for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma

    FDA Drug Approval Summary: Nelarabine (Arranon®) for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma por Martin H. Cohen, John R. Johnson, Robert Justice, Richard Pazdur

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

    FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme por Martin H. Cohen, Yuan Li Shen, Patricia Keegan, Richard Pazdur

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    FDA Drug Approval Summaries: Fulvestrant

    FDA Drug Approval Summaries: Fulvestrant por Peter Bross, Martin H. Cohen, Grant A. Williams, Richard Pazdur

    Publicado 2002
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma

    Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma por S. Huan, Richard Pazdur, Amnuay Singhakowinta, Bohumil A. Samal, Vainutis K. Vaitkevicus

    Publicado 1989
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis

    Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis por Bruce G. Redman, Richard Pazdur, Alkis P. Zingas, Rene D. Loredo

    Publicado 1987
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer

    Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer por Dickran Kazandjian, Yutao Gong, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: